Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma
Abstract: Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow transplantation (alloBMT). We previously reported th...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924007328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849708978006654976 |
|---|---|
| author | Nadeem Tabbara Marianna Zahurak Cole H. Sterling Iris Margalit Trutzer Jaroslaw Jedrych Lode J. Swinnen Ephraim J. Fuchs Javier Bolaños-Meade Nina Wagner-Johnston Richard J. Jones Richard F. Ambinder Ravi Varadhan Suman Paul |
| author_facet | Nadeem Tabbara Marianna Zahurak Cole H. Sterling Iris Margalit Trutzer Jaroslaw Jedrych Lode J. Swinnen Ephraim J. Fuchs Javier Bolaños-Meade Nina Wagner-Johnston Richard J. Jones Richard F. Ambinder Ravi Varadhan Suman Paul |
| author_sort | Nadeem Tabbara |
| collection | DOAJ |
| description | Abstract: Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow transplantation (alloBMT). We previously reported that relapsed patients with cHL treated with ICI followed by alloBMT experienced improved 3-year progression-free survival (PFS) compared with patients treated with salvage chemotherapy without ICI followed by alloBMT. In this retrospective analysis, we report the 5-year overall survival (OS), PFS, and graft-versus-host disease (GVHD) incidence in patients with cHL treated with ICI before alloBMT with post-transplantation cyclophosphamide GVHD prophylaxis. Among the 147 relapsed/refractory patients with cHL, 71 (48.3%) received ICIs and 76 (51.7%) received chemotherapy without ICIs (no-ICI) before alloBMT. We observed an improved 5-year estimated OS of 91% (ICI) vs 66% (no-ICI; hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.16-0.98; P = .046) and a 5-year estimated PFS of 84% (ICI) vs 53% (no-ICI; HR, 0.4; 95% CI, 0.2-0.81; P = .011). The 12-month cumulative incidence of grade 3 to 4 GVHD was 20% (ICI) and 7% (no-ICI; subdistribution hazard ratio (SDHR), 3.16; 95% CI, 1.13-8.81; P = .03). More frequent grade 3 to 4 acute GVHD was likely due to the higher incidence of grade 3 to 4 acute GVHD in the subset of patients with pretransplant exposure to ICI and shortened duration (60 days) of immunosuppression vs patients with long immunosuppression (day 180). These data suggest that patients with cHL treated with ICI and alloBMT experience improved OS, and the GVHD risk can be mitigated by immunosuppression until day 180. |
| format | Article |
| id | doaj-art-78f5905064d34784b8329b7eb4c43923 |
| institution | DOAJ |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-78f5905064d34784b8329b7eb4c439232025-08-20T03:15:28ZengElsevierBlood Advances2473-95292025-03-01951202120910.1182/bloodadvances.2024015048Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphomaNadeem Tabbara0Marianna Zahurak1Cole H. Sterling2Iris Margalit Trutzer3Jaroslaw Jedrych4Lode J. Swinnen5Ephraim J. Fuchs6Javier Bolaños-Meade7Nina Wagner-Johnston8Richard J. Jones9Richard F. Ambinder10Ravi Varadhan11Suman Paul12Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Dermatology, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MDDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Ravi Varadhan, Department of Oncology, Johns Hopkins University School of Medicine, Rm 1103-C, 550 N Broadway, Baltimore MD 21287;Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Correspondence: Suman Paul, Department of Oncology, Johns Hopkins University School of Medicine, CRB1, Rm 3M90, 1650 Orleans St, Baltimore, MD 21287;Abstract: Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow transplantation (alloBMT). We previously reported that relapsed patients with cHL treated with ICI followed by alloBMT experienced improved 3-year progression-free survival (PFS) compared with patients treated with salvage chemotherapy without ICI followed by alloBMT. In this retrospective analysis, we report the 5-year overall survival (OS), PFS, and graft-versus-host disease (GVHD) incidence in patients with cHL treated with ICI before alloBMT with post-transplantation cyclophosphamide GVHD prophylaxis. Among the 147 relapsed/refractory patients with cHL, 71 (48.3%) received ICIs and 76 (51.7%) received chemotherapy without ICIs (no-ICI) before alloBMT. We observed an improved 5-year estimated OS of 91% (ICI) vs 66% (no-ICI; hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.16-0.98; P = .046) and a 5-year estimated PFS of 84% (ICI) vs 53% (no-ICI; HR, 0.4; 95% CI, 0.2-0.81; P = .011). The 12-month cumulative incidence of grade 3 to 4 GVHD was 20% (ICI) and 7% (no-ICI; subdistribution hazard ratio (SDHR), 3.16; 95% CI, 1.13-8.81; P = .03). More frequent grade 3 to 4 acute GVHD was likely due to the higher incidence of grade 3 to 4 acute GVHD in the subset of patients with pretransplant exposure to ICI and shortened duration (60 days) of immunosuppression vs patients with long immunosuppression (day 180). These data suggest that patients with cHL treated with ICI and alloBMT experience improved OS, and the GVHD risk can be mitigated by immunosuppression until day 180.http://www.sciencedirect.com/science/article/pii/S2473952924007328 |
| spellingShingle | Nadeem Tabbara Marianna Zahurak Cole H. Sterling Iris Margalit Trutzer Jaroslaw Jedrych Lode J. Swinnen Ephraim J. Fuchs Javier Bolaños-Meade Nina Wagner-Johnston Richard J. Jones Richard F. Ambinder Ravi Varadhan Suman Paul Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma Blood Advances |
| title | Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma |
| title_full | Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma |
| title_fullStr | Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma |
| title_full_unstemmed | Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma |
| title_short | Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma |
| title_sort | improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed hodgkin lymphoma |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924007328 |
| work_keys_str_mv | AT nadeemtabbara improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT mariannazahurak improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT colehsterling improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT irismargalittrutzer improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT jaroslawjedrych improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT lodejswinnen improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT ephraimjfuchs improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT javierbolanosmeade improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT ninawagnerjohnston improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT richardjjones improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT richardfambinder improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT ravivaradhan improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma AT sumanpaul improvedoverallsurvivalwithcheckpointinhibitionandallogeneictransplantationinrelapsedhodgkinlymphoma |